Chelation of Theranostic Copper Radioisotopes with S-Rich Macrocycles: From Radiolabelling of Copper-64 to In Vivo Investigation [PDF]
Molecules, 2022 Copper radioisotopes are generally employed for cancer imaging and therapy when firmly coordinated via a chelating agent coupled to a tumor-seeking vector.
Marianna Tosato +11 more
doaj +2 more sources
Modifications in cellular viability, DNA damage and stress responses inflicted in cancer cells by copper-64 ions [PDF]
Frontiers in Medicine, 2023 Due to combined therapeutical emissions, a high linear energy transfer Auger-electrons with the longer ranged β− particles, 64Cu-based radiopharmaceuticals raise particular theragnostic interest in cancer, by joined therapeutic and real-time PET imaging ...
Radu M. Serban +17 more
doaj +2 more sources
PET Imaging of the Neurotensin Targeting Peptide NOTA-NT-20.3 Using Cobalt-55, Copper-64 and Gallium-68 [PDF]
Pharmaceutics, 2022 Introduction: Neurotensin receptor 1 (NTSR1) is an emerging target for imaging and therapy of many types of cancer. Nuclear imaging of NTSR1 allows for noninvasive assessment of the receptor levels of NTSR1 on the primary tumor, as well as potential ...
Hailey A. Houson +5 more
doaj +2 more sources
Antibody and Nanobody Radiolabeling with Copper-64: Solid vs. Liquid Target Approach [PDF]
Molecules, 2023 Antibody and nanobody-based copper-64 radiopharmaceuticals are increasingly being proposed as theranostic tools in multiple human diseases. While the production of copper-64 using solid targets has been established for many years, its use is limited due ...
Ivanna Hrynchak +8 more
doaj +2 more sources
Copper-64: a real theranostic agent [PDF]
Drug Design, Development and Therapy, 2018 Bianca Gutfilen,1 Sergio AL Souza,1 Gianluca Valentini2 1Department of Radiology, School of Medicine, Laboratório de Marcação de Células e Moléculas (LMCM), Universidade Federal do Rio de Janeiro, Rio de Janeiro ...
Gutfilen B, Souza SAL, Valentini G
doaj +2 more sources
Neurotensin (8-13) and Neuromedin N Neuropeptides Radiolabelling with Copper-64 Produced on Solid or Liquid Targets [PDF]
MoleculesOn the verge of a theranostic approach to personalised medicine, copper-64 is one of the emerging radioisotopes in nuclear medicine due to its exploitable nuclear and biochemical characteristics.
Diana Cocioabă +12 more
doaj +2 more sources
Editorial: In-vivo targeting of nuclear DNA with radioactive copper-64 ions [PDF]
Frontiers in Medicine, 2023 Bianca Gutfilen, Adriano Duatti
doaj +2 more sources
Chelator impact: investigating the pharmacokinetic behavior of copper-64 labeled PD-L1 radioligands [PDF]
EJNMMI Radiopharmacy and ChemistryBackground Programmed cell death ligand 1 (PD-L1) plays a critical role in the tumor microenvironment and overexpression in several solid cancers has been reported. This was associated with a downregulation of the local immune response, specifically of T-
Fabian Krutzek +2 more
doaj +2 more sources
Theragnostic 64Cu/67Cu Radioisotopes Production With RFT-30 Cyclotron
Frontiers in Medicine, 2022 64Cu and 67Cu are theragnostic pair radionuclides with promising application in the nuclear medicine. 64Cu is PET nuclide for the non-invasive diagnosis and 67Cu is beta emitter for therapy of various cancers. This study discusses optimization efforts in
Jun Young Lee +8 more
doaj +1 more source
Preparation and Preliminary Biodistribution Study of 64Cu-NOTA-NOC
Journal of Isotopes, 2021 The radiolabeling of somatostatin octapeptide analogue NOTA-NOC with 64Cu was carried out. The preliminary study of 64Cu-NOTA-NOC on the in vitro stability, the lipid-water partition coefficient, and the distribution in normal and tumor-bearing mice was ...
ZHAO Hailong;LI Zequang;LUO Tianwei;HUANG Xuhu;WANG Ning;CHEN Mengyi;XU Lin;SHI Xudong;DENG Xuesong;LI Hongyu
doaj +1 more source